Prostatic Calculi (Investigational Adjunct)
Investigational adjunct for symptomatic prostatic calculi associated with chronic prostatitis; targeted antibiotics, alpha blockers, and selective transurethral resection remain evidence-based.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for prostatic calculi. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational; the prostate is anatomically inaccessible to topical agents.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials exist for hirudotherapy in prostatic calculi; only mention-level traditional-medicine references. Prostatic calculi are common incidental findings, often asymptomatic. If symptomatic and associated with chronic bacterial prostatitis, evidence-based management is prolonged culture-guided targeted antibiotic therapy, alpha-blockers for urinary symptoms, and selectively transurethral resection of the prostate (TURP) for refractory cases.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the perineum for 5 to 14 days
- Local skin infection or Aeromonas infection in a region with frequent bacterial colonization
- Compounding bacterial prostatitis if untreated infection is present
- Allergic reaction to leech saliva
- Delay of evidence-based culture-guided antibiotics, alpha-blockers, or TURP
- Hypothetical risk if a leech detaches near the urethra (urethral bleeding)
- Wer dies nicht in Betracht ziehen sollte
- Anyone with untreated bacterial prostatitis (treat infection first)
- Anyone with an indwelling urinary catheter
- Anyone within the recovery window of prostate biopsy or surgery
- Patients who cannot maintain perineal cleanliness during the bleeding window
- Patients on anticoagulants or with severe anemia
- Patients offered trans-rectal or peri-urethral placement (these are not appropriate)
- Was Sie Ihren Kliniker fragen sollten
- Has bacterial prostatitis been ruled out by culture, and what antibiotic course has been completed?
- Have I had pelvic imaging to confirm calculi as the symptomatic driver?
- Have alpha-blockers been trialed for symptom relief?
- Has TURP been considered for refractory symptoms?
- Where exactly will the leech be placed — confirm it is perineal skin only, not trans-rectal?
- What is the realistic expected benefit, given the prostate is anatomically deep and inaccessible to topical agents?
- Wann dringende medizinische Versorgung suchen
- Inability to urinate (acute urinary retention)
- Fever above 38.0 C / 100.4 F, chills, or rigors
- Visible blood in urine or perineal hematoma
- Severe lower abdominal or pelvic pain
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, pus, or red streaks at the bite site
Was dies NICHT bedeutet
- It does not dissolve or remove prostatic stones — the prostate is too deep for topical effects.
- It does not replace targeted antibiotic therapy when prostatic calculi harbor bacterial biofilms.
- It does not substitute for TURP when refractory disease warrants surgical management.
- Only anecdotal mention exists in traditional-medicine literature.
Sicherheits-Querverweise
Clinical Profile
- Category
- urogenital
- ICD-10
- N42.0, N41.1
- Safety tier
- high
Evidence Summary
Prostatic calculi are common incidental findings, often asymptomatic, but in some patients harbor biofilms that perpetuate chronic bacterial prostatitis. Evidence-based management depends on context: if asymptomatic, observation only. If associated with chronic prostatitis, prolonged targeted antibiotic therapy guided by culture, alpha-blockers for urinary symptoms, and (selectively) transurethral resection of the prostate (TURP) for refractory cases. No published controlled trials of hirudotherapy exist for prostatic calculi. The prostate is anatomically deep and inaccessible to topical agents; any rationale for hirudotherapy is purely speculative. Perineal placement carries infection risk in this often-bacterial context.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Untreated bacterial prostatitis (treat infection first)
- Indwelling urinary catheter
- Recent prostate biopsy or surgery
- Patient unable to maintain perineal cleanliness during bleed
Related Conditions
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.